文献速递糖尿病

随机非空腹C肽检测可识别低血糖高风险的胰岛素治疗2型糖尿病患者

Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia.
PubMed 文献 · Diabetologia · 2017-10-05

本研究比较了17例严重胰岛素缺乏(rCP<200 pmol/l)与17例保留内源性胰岛素(rCP>600 pmol/l)的胰岛素治疗2型糖尿病患者的持续葡萄糖监测指标,并在256例2型糖尿病和209例1型糖尿病患者中评估rCP与问卷低血糖的关系。低rCP与更高的血糖变异性和低血糖频率相关,rCP可作为评估低血糖风险的实用、稳定且廉价的生物标志物。

要点

  • rCP<200 pmol/l的胰岛素治疗2型糖尿病患者血糖标准差更高(4.2 vs 3.0 mmol/l,p<0.001)。
  • rCP<200 pmol/l者持续低血糖≤4 mmol/l比例更高(94% vs 41%,p<0.001)。
  • rCP<200 pmol/l者自我报告低血糖频率约为对照的2倍(OR 2.0,p<0.001)。

核心结论

  • 低rCP与胰岛素治疗2型糖尿病患者的血糖变异性增加和低血糖相关,是评估低血糖风险的实用、稳定且廉价的生物标志物。

研究设计与样本

  • 研究比较了17例严重胰岛素缺乏(rCP<200 pmol/l)与17例匹配的保留内源性胰岛素(rCP>600 pmol/l)的胰岛素治疗2型糖尿病患者的持续葡萄糖监测指标。
  • 在256例胰岛素治疗2型糖尿病患者和209例1型糖尿病对照中评估rCP与问卷低血糖的关系。

主要发现

  • 低C肽组与高C肽组相比,血糖标准差为4.2(95% CI 3.7, 4.6)vs 3.0(2.6, 3.4)mmol/l(p<0.001)。
  • 低C肽组与高C肽组相比,经历持续低血糖≤4 mmol/l的比例为94% vs 41%(p<0.001),人均每周低血糖发生率为5.5(4.4, 6.7)vs 2.1(1.4, 2.9)次(p=0.004),人均每周平均持续时间为630(619, 643)vs 223(216, 230)分钟(p=0.01)。
  • 低C肽组与高C肽组相比,低血糖≤3 mmol/l的发生率分别为1.8(1.2, 2.6)vs 0.4(0.1, 0.8)次/人/周(p=0.04),且仅发生在夜间。
  • 在胰岛素治疗2型糖尿病人群队列中,rCP<200 pmol/l者自我报告低血糖频率是对照的2倍(OR 2.0,p<0.001),导致意识丧失或癫痫发作的低血糖事件率是对照的5倍(OR 5.0,p=0.001)。
  • 1型和2型糖尿病患者中自我报告低血糖与C肽的关系相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of this study was to determine whether random non-fasting C-peptide (rCP) measurement can be used to assess hypoglycaemia risk in insulin-treated type 2 diabetes. METHODS: We compared continuous glucose monitoring-assessed SD of blood glucose and hypoglycaemia duration in 17 patients with insulin-treated type 2 diabetes and severe insulin deficiency (rCP < 200 pmol/l) and 17 matched insulin-treated control patients with type 2 diabetes but who had preserved endogenous insulin (rCP > 600 pmol/l). We then assessed the relationship between rCP and questionnaire-based measures of hypoglycaemia in 256 patients with insulin-treated type 2 diabetes and a comparison group of 209 individuals with type 1 diabetes. RESULTS: Continuous glucose monitoring (CGM)-assessed glucose variability and hypoglycaemia was greater in individuals with rCP < 200 pmol/l despite similar mean glucose. In those with low vs high C-peptide, SD of glucose was 4.2 (95% CI 3.7, 4.6) vs 3.0 (2.6, 3.4) mmol/l (p < 0.001). In the low-C-peptide vs high-C-peptide group, the proportion of individuals experiencing sustained hypoglycaemia ≤ 4 mmol/l was 94% vs 41% (p < 0.001), the mean rate of hypoglycaemia was 5.5 (4.4, 6.7) vs 2.1 (1.4, 2.9) episodes per person per week (p = 0.004) and the mean duration was 630 (619, 643) vs 223 (216, 230) min per person per week (p = 0.01). Hypoglycaemia ≤ 3 mmol/l was infrequent in individuals with preserved C-peptide (1.8 [1.2, 2.6] episodes per person per week vs 0.4 [0.1, 0.8] episodes per person per week for low vs high C-peptide, p = 0.04) and only occurred at night. In a population-based cohort with insulin-treated type 2 diabetes, self-reported hypoglycaemia was twice as frequent in those with rCP < 200 pmol/l (OR 2.0, p < 0.001) and the rate of episodes resulting in loss of consciousness or seizure was five times higher (OR 5.0, p = 0.001). The relationship between self-reported hypoglycaemia and C-peptide was similar in individuals with type 1 and type 2 diabetes. CONCLUSIONS/INTERPRETATION: Low rCP is associated with increased glucose variability and hypoglycaemia in patients with insulin-treated type 2 diabetes and represents a practical, stable and inexpensive biomarker for assessment of hypoglycaemia risk.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Hope SV, Knight BA, Shields BM, et al. Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia. 2017. PMID: 28983693. doi:10.1007/s00125-017-4449-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。